Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma

Iodine-refractory thyroid cancer remains a major therapeutic challenge. Beyond tyrosine kinase inhibitors, other therapies that have been explored include tropomyosin kinase inhibitors, redifferentiation attempts, and peptide receptor radionuclide therapy targeting somatostatin receptors (SSTRs).